Buprenorphine-an opioid used to treat opioid addiction, moderate acute pain and moderate chronic pain

Buprenorphine is used in medication-assisted treatment (MAT) to help people reduce or quit their use of heroin or other opiates

Buprenorphine-an opioid used to treat opioid addiction, moderate acute pain and moderate chronic pain

Buprenex; Temgesic; Buprenorfina; Buprenorphinum

Addnok, Bunogesic, Buprigesic, Buprine, Buprinor, Norphin, Pentorel, Qudict, Tidigesic.

(1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,?.0¹,?.0?,¹?.0?,¹²]icosa-7,9,11-trien-11-ol.

Buprenorphine's analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-Opioids receptor antagonist, binding to kappa and mu receptors results in hyper polarization and reduced neuronal excitability. Furthermore, buprenorphine slowly dissociates from its receptor. 

The recommended dose is 0.3 to 0.6 mg by IM/IV/SC routes.0.2 to 0.4 mg ¾ times a day sublingual.

Prescribed for moderate to severe pain.

Sedation, nausea, dizziness, hypotension, vertigo, miosis, headache, respiratory or CNS depression; hypoventilation, tachycardia, urinary retention, bradycardia, coma, vomiting, drowsiness, sweating, confusion, dry mouth, diaphoresis, withdrawal syndrome.

·       Enhanced depressant effects with other CNS depressants e.g. anaesthetics, alcohol, anxiolytics, hypnotics, TCAs and antipsychotics. Diazepam may produce respiratory and cardiac collapse.

·       Plasma-buprenorphine concentrations may be affected when co-administered with drugs that induce or inhibit cytochrome P450 isoenzyme CYP3A4.

• Convulsive disorders; head injuries; comatose patients; increased intracranial pressure; respiratory depression and obstructive airway disease; patients on established Opioids agonists.
• Acute alcoholism; 

Store at 15-30°C.

Molecular weight

467.6401

Molecular formula

C29H41NO4

CAS number

52485-79-7

Precautions

• Infants/neonates.

• Hepatic or renal disease; pregnancy, lactation; hypothyroidism; adrenocortical insufficiency; asthma; prostatic hyperplasia; shock; hypotension; myasthaenia gravis; inflammatory or obstructive bowel disorders.
• Reduce dose in elderly and debilitated patients.
• May precipitate withdrawal symptoms in narcotic addicts.